MAPT and Alzheimer disease: CSF p‐tau is also an excellent prognosis biomarker in AD since it finely predicts progression from cognitively unimpaired (CU) to mild cognitive impairment (MCI) and, eventually, to AD dementia (Roe et al, 2013; Petersen et al, 2013; Ferreira et al, 2014).